GSTM1 and Schnyder corneal dystrophy: To design our sequential multi-cohort model, evidence from a recent risk-reduction meta-analysis of the projected benefits of increased Hb concentrations in patients with SCD was combined with the improvements in Hb levels demonstrated in the phase 3 HOPE trial of voxelotor in patients aged ≥12 years.